Antibodies

Antibodies attacking virus
#Antibodies #Chiba University #Covid-19 #Immune system

Could auto-antibodies be linked to severe Covid-19?

Researchers have revealed that auto-antibodies block interferon signalling, contributing to severe Covid-19 by impairing the patient’s immune response. Scientists have found that some people who suffered from Covid-19 had auto-antibodies targeting their own type 1 interferons, which are important immune signalling proteins. Factors such… Read More

#News #Trending News

Blood cancer
#Antibodies #Blood cancer #CAR-T #Cell therapy #Clinical trials #Events #Haematology

EHA2024: Industry shares latest drug research in blood cancers

A number of key findings in haematological malignancies were revealed at this year’s European Hematology Association (EHA) Congress, which was held in Madrid, Spain 13-16 June. Ibrutinib and talquetamab, Johnson & Johnson Johnson & Johnson shared clinical trial results for its drug candidates Talvey (talquetamab) and… Read More

#Cancer Research #News #Trending News

Antibody drug conjugate
#Antibodies #Antibody drug conjugate (ADC) #Cancer research #Funding #Pheon Therapeutics #Solid tumours

$120m raised to develop differentiated ADC pipeline 

Pheon Therapeutics has completed a $120m Series B financing to fund the development of its pipeline of next generation ADCs for a wide range of hard-to-treat cancers.  The new financing will be used to further advance Pheon’s differentiated ADC pipeline through clinical proof of concept. The first three assets are… Read More

#Business & Investment #Cancer Research #News

#Antibodies #Artificial intelligence (AI) #Monoclonal antibodies #Therapeutic Antibodies

Therapeutic antibody potential in 2024

DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab)1. This won't come as a surprise when you look at industry milestones… Read More

#Exclusive Content

Monoclonal antibody
#Antibodies #Drug discovery #eBook #Monoclonal antibodies #Therapeutic Antibodies

eBook: Drug discovery and the impact of mAbs

The low toxicity and high specificity of monoclonal antibodies (mAbs) continue to make them an appealing target for clinical research and investment. During 2023, 16 antibody therapeutics were granted approvals in the US or EU, either for the first time or for a new indication, covering uses as… Read More

#News

Monoclonal antibodies eBook cover
#Antibodies #Drug discovery #eBook #Monoclonal antibodies #Therapeutic Antibodies

Drug discovery and the impact of mAbs

This eBook, sponsored by Thermo Fisher Scientific, explores the impact of monoclonal antibodies (mAbs) on the treatment of cancer, autoimmune and infectious diseases, and inflammatory conditions, as well as the latest clinical research and where the innovation in mAb development might be in the future. Download this exclusive eBook to… Read More

#DDW eBooks #Intelligence

Human antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Opportunity in the antibody market: Hear from the experts

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

#Antibodies #Artificial intelligence (AI) #Biologics #Investment #Seed funding #Start-ups

AI drug discovery company Xaira launches with $1b investment

Xaira Therapeutics, a joint incubation by ARCH Venture Partners and Foresite Labs, has launched with more than $1 billion of committed capital from lead investors. Xaira is building a platform for drug discovery and development that it hopes will advance multiple drug programmes and unlock biological… Read More

#News #Start-up Zone #Trending News

#Antibodies #Antiverse #Artificial intelligence (AI) #Generative AI #Oncology

Advancing antibody cancer therapeutics with AI

Antiverse is an artificial intelligence (AI)-driven company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Murat Tunaboylu, Co-founder and CEO of Antiverse, speaks with Megan Thomas about how AI can advance therapeutic antibody design. Megan T: How is Antiverse using AI in… Read More

#Cancer Research #Exclusive Content

Monoclonal antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Webinar: How can we develop better therapeutic antibodies?

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

#Antibodies #Cancer research #Oncology #Phase III trial #Therapeutic Antibodies

Improving the standard of care: Inside the DUO-E trial

Professor Shannon Westin is principal investigator of the DUO-E trial, here she speaks to DDW’s Megan Thomas about why the standard of care needs improving and the impact of therapeutic antibodies such as durvalumab. The DUO-E trial is a three-arm, randomised, double-blind, placebo-controlled, multicentre Phase III trial assessing the combination… Read More

#Cancer Research #Exclusive Content

Antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Webinar: Innovations and opportunities in the therapeutic antibody market

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

#Absci #Antibodies #Artificial intelligence (AI) #Biologics #Generative AI #Interview

The next generation of AI

Reece Armstrong speaks to Sean McClain, Founder & CEO of Absci, about the rise of generative AI in life sciences. The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications.  Last year, a lot of focus was placed on artificial intelligence (AI) both… Read More

#Exclusive Content

#Alzheimer's #Antibodies #Monoclonal antibodies #Neurodegenerative disorders #Therapeutic Antibodies

Therapeutic antibodies in the fight against Alzheimer’s

ImmunoBrain Checkpoint (IBC) is currently dosing patients in a clinical trial with its monoclonal antibody for Alzheimer’s disease (AD). DDW’s Megan Thomas caught up with Professor Michal Schwartz to learn more about her work and the work being carried out by IBC. MT: Can you provide an overview of your… Read More

#Exclusive Content

#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Where is the opportunity in the therapeutic antibody market?

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News